CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Rainone, Veronica ^a   Dubois, Gregor ^b   Temchura, Vladimir ^c   Überla, Klaus ^c   Clivio, Alberto ^a   Nebuloni, Manuela ^a   Lauri, Eleonora ^a   Trabattoni, Daria ^a   Veas, Francisco ^b   Clerici, Mario ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIV MONTPELLIER   (France)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CCL28 CHEMOKINE; CD19 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR10; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS 1 IIIB VIRUS LIKE PARTICLE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; INTERLEUKIN 4; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; BETA CHEMOKINE; CCL19 PROTEIN, MOUSE; CCL28 PROTEIN, MOUSE; CCR10 PROTEIN, MOUSE; CCR3 PROTEIN, MOUSE; CHEMOKINE RECEPTOR CCR3; RECOMBINANT PROTEIN; SECRETORY IMMUNOGLOBULIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELL HOMING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN A SECRETING PLASMA CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; MONOTHERAPY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PLASMA CELL; PROTEIN EXPRESSION; SPLEEN CELL; VACCINATION; VAGINA SECRETION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TYPING; ANIMAL; CELL MEMBRANE; CELL MOTION; COLON; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; SECRETION; SERODIAGNOSIS; SPECIES DIFFERENCE; SPLEEN; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; ANTIGENS, CD19; CELL MEMBRANE; CELL MOVEMENT; CHEMOKINE CCL19; CHEMOKINES, CC; COLON; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; INTESTINAL MUCOSA; MICE; NEUTRALIZATION TESTS; PLASMA CELLS; RECEPTORS, CCR10; RECEPTORS, CCR3; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; SPLEEN; VIRION;

EID: 80055111983     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026979     Document Type: Article

References (55)

1. Iijima H, Takahashi I, Kiyono H, (2001) Mucosal immune network in the gut for the control of infectious diseases. Rev Med Virol 11: 117-133.
2. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, (1992) The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10: 75-88.
3. Brandtzaeg P, (2003) Role of secretory antibodies in the defence against infections. Int J Med Microbiol 293: 3-15.
4. Brandtzaeg P, (2006) Induction of scretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-5484.
5. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
6. Wang W, Soto H, Oldham ER, Buchanan ME, Homey B, et al. (2000) Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J Biol Chem 275: 22313-22323.
7. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, et al. (2004) Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 170: 1136-1140.
8. Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, et al. (2003) CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 111: 1001-1010.
9. Williams IR, (2004) Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol Res 29: 283-292.
10. Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, et al. (2006) Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol 177: 593-603.
11. Wilson E, Butcher EC, (2004) CCL28 controls immunoglobulin (Ig) A plasma cell accumulation in the lactating mammary gland and IgA antibody transfer to the neonate. J Exp Med 200: 805-809.
12. Castelletti E, Lo Caputo S, Kuhn L, Borelli M, Gajardo J, et al. (2007) The Mucosae-Associated Epithelial Chemokine Modulates Immunity in HIV Infection. Plos One 2: e969.
13. Grgacic EVL, Anderson DA, (2006) Virus-like particles: Passport to immune recognition. Methods 40: 60-65.
14. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT, (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89: 12180-12184.
15. Roy P, Noad R, (2009) Virus-like particles as a vaccine delivery system: myths and facts. Adv Exp Med Biol 655: 145-158.
16. Kang SM, Pushko P, Bright RA, Smith G, Compans RW, et al. (2009) Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 333: 269-289.
17. Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, et al. (2004) M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 82: 506-516.
18. Young KR, McBurney SP, Karkhanis LU, Ross TM, (2006) Virus-like particles: Designing an effective AIDS vaccine. Methods 40: 98-117.
19. Rovinski B, Haynes JR, Cao SX, James O, Sia C, et al. (1992) Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J Virol 66: 4003-4012.
20. Boyer JD, Kim J, Ugen K, Cohen AD, Ahn L, et al. (1999) HIV-1 DNA vaccines and chemokines. Vaccine 17: S53-S64.
21. Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB, (2000) Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 20: 487-98.
22. Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, Zharikova D, et al. (2010) Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Therapy 17: 72-82.
23. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, et al. (2007) A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366: 245-262.
24. Demberg T, Robert-Guroff M, (2009) Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 28: 20-48.
25. McGowan I, (2006) Microbicides: a new frontier in HIV prevention. Biologicals 34: 241-255.
26. Watkins DI, (2010) HIV vaccine development. Top HIV Med 18: 35-36.
27. Vaccari M, Poonam P, Franchini G, (2010) Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Exper Rev Vaccines 9: 997-1005.
28. Plotkin SA, (2010) The RV144 Thai HIV vaccine trial. Hum Vaccin 6: 157-163.
29. D'Cruz OJ, Uckun FM, (2004) Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 10: 315-336.
30. Desimmie BA, (2010) AIDS 2010-XVIII International AIDS Conference. I Drugs 13: 622-625.
31. Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, et al. (2000) A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol 165: 2943-2949.
32. Morteau O, Gerard C, Lu B, Ghiran S, Rits M, et al. (2008) An indispensable role for the chemokine receptor CCR10 in IgA antibody-secreting cell accumulation. J Immunol 181: 6309-6315.
33. Hieshima K, Kawasaki Y, Hanamoto H, Nakayama T, Nagakubo D, et al. (2004) CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol 173: 3668-3675.
34. Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, et al. (2003) A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 170: 3799-3805.
35. Wu X, Hall S, Jackson S, (2003) Tropism-restricted neutralization by secretory IgA from parotid saliva of HIV type 1-infected individuals. AIDS Res. Hum Retroviruses 19: 275-281.
36. Soderlund J, Hirbod T, Goh LE, Andersson J, Broliden K, (2004) Presence of HIV-1 neutralizing IgA antibodies in primary HIV-1 infected patients. Scand J Infect Dis 36: 663-669.
37. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Blé C, et al. (1997) HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3: 1250-1257.
38. Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, et al. (1999) Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. J Infect Dis 179: 59-68.
39. Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, et al. (2004) Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. J Virol 78: 7016-7022.
40. Clerici M, Barassi C, Devito C, Pastori C, Piconi, S et al, (2001) Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 16: 1731-1741.
41. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, et al. (2000) Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 165: 5170-5176.
42. Bomsel M, Pastori C, Tudor D, Alberti C, Garcia S, et al. (2007) Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS 21: 13-22.
43. Dandekar S, (2007) Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 4: 10-15.
44. Centlivre M, Sala M, Wain-Hobson S, Berkhout B, (2007) In HIV-1 pathogenesis the die is cast during primary infection. AIDS 21: 1-11.
45. Lehner T, Hoelscher M, Clerici M, Gotch F, Pedneault L, et al. (2005) European Union and EDCTP strategy in the global context: Recommendations for preventive HIV/AIDS vaccines research. Vaccine 23: 5551-5556.
46. Lehner T, Anton PA, (2002) Mucosal immunity and vaccination against HIV. AIDS 16: S125-S132.
47. Kweon MN, Yamamoto M, Kajiki M, Takahashi I, Kiyono H, (2000) Systemically derived large intestinal CD4+ Th2 cells play a central role in STAT6-mediated allergic diarrhea. J Clin Invest 106: 199-206.
48. Kweon MN, Takahashi I, Yamamoto M, Jang MH, Suenobu N, et al. (2002) Development of antigen induced colitis in SCID mice reconstituted with spleen derived memory type CD4+ CD45RB+ T cells. Gut 50: 299-306.
49. Chang SY, Cha HR, Uematsu S, Akira S, Igarashi O, et al. (2008) Colonic patches direct the cross-talk between systemic compartments and large intestine independently of innate immunity. J Immunol 180: 1609-1618.
50. Ponath PD, Qin S, Post TW, Wang J, Wu L, et al. (1996) Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183: 2437-2448.
51. Sallusto F, Mackay CR, Lanzavecchia A, (1997) Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277: 2005-2007.
52. Jinquan T, Jacobi HH, Jing C, Millner A, Sten E, et al. (2003) CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells. J Immunol 171: 1722-1731.
53. Gao JL, Sen AI, Kitaura M, Yoshie O, Rothenberg ME, et al. (1996) Identification of a mouse eosinophil receptor for the CC chemokine eotaxin. Biochem Biophys Res Commun 223: 679-684.
54. Murphy PM, (1996) Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev 7: 47-64.
55. Post TW, Bozic CR, Rothenberg ME, Luster AD, Gerard N, et al. (1995) Molecular characterization of two murine eosinophil beta chemokine receptors. J Immunol 155: 5299-5305.